Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers
Authors
John D. Hooper (ORCID: https://orcid.org/0000-0003-1054-8486)
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers
John D. Hooper, Madeline Gough, Kayden K.X. Kwah, Justin B. Goh et al.
Citations
3 citations
Journal
Clinical Cancer Research
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
3.14
article
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers
John D. Hooper, Madeline Gough, Kayden K.X. Kwah, Justin B. Goh, Kristofer J. Thurecht, Tashbib Khan, Cameron Snell, Thomas Kryza, Brian Wan-Chi Tse, Saikat Ghosh, Kaltin Ferguson, Nicholas L. Fletcher, Laura Jane Bray, Christopher Pyke, Zachary H. Houston, Catherine Y.J. Lee, Kamil A. Sokolowski, Elgene Lim, Cheng Liu, Biao Sun, Yaowu He, Rebecca Rogers, Lashith Wickramasuriya
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
Clinical Cancer ResearchVol. 31(8)
Institutions
Translational Research Institute (AU), Mater Health Services (AU), Australian Research Council (AU), Garvan Institute of Medical Research (AU), Queensland University of Technology (AU), The University of Queensland (AU), Peter MacCallum Cancer Centre (AU), Envoi Specialist Pathologists (AU), Mater Research (AU), National Imaging Facility (AU), IIT@Harvard (US), Services Australia (AU)